Health Economics›Gastric cancer›Metastatic or locally advanced disease subsequent lines of therapy

Metastatic or locally advanced disease subsequent lines of therapy

Gastric cancer · 22 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Trifluridine and tipiracil monotherapy Variant #01	—	R 1 013 418	28d	—	5.7 mo	—	—	1
Regorafenib monotherapy Variant #06	—	R 307 423	28d	2.6 mo	4.5 mo	3	R 922 268 PFS proxy	2
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	9.1 mo	—	—	1
Paclitaxel and Ramucirumab Variant #01	—	R 98 010	28d	4.1 mo	10.5 mo	5	R 490 052 PFS proxy	3
Paclitaxel and Ramucirumab Variant #01	ERBB2	R 98 010	28d	4.1 mo	10.5 mo	5	R 490 052 PFS proxy	3
Trastuzumab deruxtecan monotherapy Variant #01	ERBB2	R 81 019	21d	—	13.6 mo	—	—	2
Ramucirumab monotherapy Variant #01	—	R 48 173	14d	—	5.2 mo	—	—	1
nab-Paclitaxel monotherapy Variant #01	—	R 45 710	28d	—	11.1 mo	—	—	1
Fluorouracil, Folinic acid, Mitomycin Variant #01	—	R 11 847	56d	—	—	—	—	—
Irinotecan and Mitomycin Variant #01	—	R 2 896	28d	—	—	—	—	—
Paclitaxel monotherapy Variant #46	ERBB2	R 2 220	28d	2.9 mo	8.3 mo	4	R 8 878 PFS proxy	17
Paclitaxel monotherapy Variant #46	—	R 2 220	28d	2.9 mo	8.3 mo	4	R 8 878 PFS proxy	17
Paclitaxel and Fruquitinib Variant #01 Partial	—	R 1 665	28d	5.6 mo	9.6 mo	7	R 11 652 PFS proxy	2
Docetaxel monotherapy N/A - secondary systemic drug	ERBB2	R 243	28d	1.8 mo	5.3 mo	2	R 486 PFS proxy	4
Docetaxel monotherapy N/A - secondary systemic drug	—	R 243	28d	1.8 mo	5.3 mo	2	R 486 PFS proxy	4
Irinotecan monotherapy N/A - secondary systemic drug	ERBB2	R 47	42d	2.3 mo	8.4 mo	2	R 95 PFS proxy	9
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	2.3 mo	8.4 mo	2	R 95 PFS proxy	9
Apatinib monotherapy Variant #01 Partial	—	—	28d	1.8 mo	5.8 mo	2	—	2
Nivolumab monotherapy Variant #01 Partial	—	—	14d	1.8 mo	5.3 mo	4	—	2
Placebo Partial	—	—	—	0.9 mo	4.0 mo	—	—	6
Irinotecan liposomal monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Best supportive care Partial	—	—	—	—	3.7 mo	—	—	4

22 of 22 regimens shown